dc.contributor.author | Yildiz, Anil | |
dc.contributor.author | Saip, Pinar | |
dc.contributor.author | Ahmed, Melin Aydan | |
dc.contributor.author | Aydiner, Adnan | |
dc.contributor.author | VATANSEVER, Sezai | |
dc.contributor.author | DOĞAN, İzzet | |
dc.contributor.author | Khanmammadov, Nijat | |
dc.date.accessioned | 2023-10-10T10:56:37Z | |
dc.date.available | 2023-10-10T10:56:37Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | DOĞAN İ., Khanmammadov N., Ahmed M. A., Yildiz A., Saip P., Aydiner A., VATANSEVER S., "Crizotinib in Metastatic ALK mutant Non-small Cell Lung Cancer Patients: A Single Centre Experience", CLINICAL CANCER INVESTIGATION JOURNAL, sa.3, ss.25-29, 2022 | |
dc.identifier.issn | 2278-0513 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_1018c351-6d7c-4ec7-80a5-26e11142d19f | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/189617 | |
dc.identifier.uri | https://avesis.istanbul.edu.tr/api/publication/1018c351-6d7c-4ec7-80a5-26e11142d19f/file | |
dc.identifier.uri | https://doi.org/10.51847/87n2fddtb1 | |
dc.description.abstract | The goal of this study was to evaluate the efficacy of crizotinib in patients with ALK-positive metastatic lung cancer. The patients' data were analyzed retrospectively. Cox regression and Kaplan-Meier methods were used to perform survival analyses. A total of 25 patients were involved in the study. Thirteen (52%) patients were male, and the average age was 55 (range, 30-80). 23 (92%) of the patients were de-novo metastatic. Brain metastases were present in 32% and liver metastases in 20% of the patients. Before crizotinib treatment, 64% of the patients had received chemotherapy, and 20% had received palliative radiotherapy. Progression-free survival was found as 16.8 (CI 95%, 5.7-27.9) months. Grade 1-2 side effects were detected in 36% of the patients, and grade 3-4 side effects were observed in 12%. After progression, 13 (52%) patients received 2nd series ALK inhibitors (alectinib, ceritinib, and lorlatinib) or chemotherapy. The median overall survival (OS) was found as 44.2 (95% CI, 28.5-59.9) months. The four-year OS rate was 37.4%. In the multivariate analysis, the ALK positivity ratio (p=0.02) was determined as a statistically significant factor affecting OS. We showed efficacy data of crizotinib in patients with ALK mutant metastatic non-small cell lung cancer. Crizotinib is an effective and safe therapy for patients with ALK mutant metastatic non-small cell lung cancer. Also, we found that the ALK positivity ratio was prognostic for OS. | |
dc.language.iso | eng | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Onkoloji | |
dc.subject | İç Hastalıkları | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | ONKOLOJİ | |
dc.title | Crizotinib in Metastatic ALK mutant Non-small Cell Lung Cancer Patients: A Single Centre Experience | |
dc.type | Makale | |
dc.relation.journal | CLINICAL CANCER INVESTIGATION JOURNAL | |
dc.contributor.department | İstanbul Teknik Üniversitesi , , | |
dc.identifier.issue | 3 | |
dc.identifier.startpage | 25 | |
dc.identifier.endpage | 29 | |
dc.contributor.firstauthorID | 4309442 | |